KYTX vs. NVAX, RXRX, BEAM, KYMR, FUSN, SANA, NMRA, VIR, BCRX, and CGEM
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Novavax (NVAX), Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM), Kymera Therapeutics (KYMR), Fusion Pharmaceuticals (FUSN), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), BioCryst Pharmaceuticals (BCRX), and Cullinan Therapeutics (CGEM). These companies are all part of the "biological products, except diagnostic" industry.
Novavax (NASDAQ:NVAX) and Kyverna Therapeutics (NASDAQ:KYTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Kyverna Therapeutics has lower revenue, but higher earnings than Novavax.
Novavax presently has a consensus target price of $17.50, suggesting a potential upside of 16.43%. Kyverna Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 241.18%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Novavax.
In the previous week, Novavax had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for Novavax and 4 mentions for Kyverna Therapeutics. Novavax's average media sentiment score of 1.07 beat Kyverna Therapeutics' score of 0.63 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.
Novavax received 838 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Kyverna Therapeutics an outperform vote while only 74.14% of users gave Novavax an outperform vote.
53.0% of Novavax shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 0.9% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Kyverna Therapeutics has a net margin of 0.00% compared to Kyverna Therapeutics' net margin of -40.01%.
Summary
Kyverna Therapeutics beats Novavax on 9 of the 14 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
